Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

38 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identifying actionable targets through integrative analyses of GEM model and human prostate cancer profiling (Illumina)

ABSTRACT: Here we profile prostate cancers derived from GEM models of prostate cancer representative of human prostate cancer Total RNA was isolated from established prostate cancers in 3 GEM models of prostate cancer - PB-MYC, Pten-/-, Pten-/- p53-/-

ORGANISM(S): Mus musculus

SUBMITTER: Jeffrey Zhao

PROVIDER: E-GEOD-61379 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling.

Wanjala Jackie J Taylor Barry S BS Chapinski Caren C Hieronymus Haley H Wongvipat John J Chen Yu Y Nanjangud Gouri J GJ Schultz Nikolaus N Xie Yingqiu Y Liu Shenji S Lu Wenfu W Yang Qing Q Sander Chris C Chen Zhenbang Z Sawyers Charles L CL Carver Brett S BS

Molecular cancer therapeutics 20141107 1

Copy-number alterations (CNA) are among the most common molecular events in human prostate cancer genomes and are associated with worse prognosis. Identification of the oncogenic drivers within these CNAs is challenging due to the broad nature of these genomic gains or losses which can include large numbers of genes within a given region. Here, we profiled the genomes of four genetically engineered mouse prostate cancer models that reflect oncogenic events common in human prostate tumors, with t ...[more]

PMID: 25381262

Similar Datasets

Identifying actionable targets through integrative analyses of GEM model and human prostate cancer profiling [Agilent]

Project description:Here we prolife prostate cancers derived from GEM models of prostate cancer representative of human prostate cancer Total DNA was isolated from established prostate cancers in 4 GEM models of prostate cancer - PB-MYC, Pten-/-, Pten-/- p53-/-, Pten-/- Rosa26-ERG, and 3 cell lines derived from GEM models including CaP8, MYC CaP, and MPC3 and normalized to wild-type prostate of litter-mate mice of same genetic background strain

2015-02-20 | E-GEOD-61382 | biostudies-arrayexpress

Identifying actionable targets through integrative analyses of GEM model and human prostate cancer profiling (Illumina)

Project description:Here we profile prostate cancers derived from GEM models of prostate cancer representative of human prostate cancer

2015-02-20 | GSE61379 | GEO

Identifying actionable targets through integrative analyses of GEM model and human prostate cancer profiling [Agilent]

Project description:Here we prolife prostate cancers derived from GEM models of prostate cancer representative of human prostate cancer

2015-02-20 | GSE61382 | GEO

Identifying actionable targets through integrative analyses of GEM model and human prostate cancer profiling

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2015-02-20 | E-GEOD-61383 | biostudies-arrayexpress

Chromatin interaction of ERG and AR in established prostate cancer

Project description:The current study defines the how ERG, PTEN, and AR inteact to regulate the transciptome in established prostate cancers. Prostate cancer organoids were derived from established prostate cancer in GEM models harboring ERG over-expression and/or loss of PTEN and cultured in vitro using prostate epithelial organoid culture conditions. The established organoids were then isolated as individual clones in triplicate and CRISPR strategies were employeed to knock out ERG and AR. ChIP seq was performed under standard growth and media conditions.

2019-03-28 | GSE112414 | GEO

Impact of ERG and PTEN loss on RNA expression

Project description:The current study defines the how ERG, PTEN, and AR inteact to regulate the transciptome in established prostate cancers. Prostate cancer organoids were derived from established prostate cancer in GEM models harboring ERG over-expression and/or loss of PTEN and cultured in vitro using prostate epithelial organoid culture conditions. The established organoids were then isolated as individual clones in triplicate and CRISPR strategies were employeed to knock out ERG and AR. RNA was isolated under physiologic steady state growth conditions and 24 hour treatment with the AR inhbitor MDV3100 in a subset of ERG-PTEN CRISPR ERG organoids.

2018-03-29 | GSE112469 | GEO

Identifying actionable targets through integrative analyses of GEM model and human prostate cancer profiling

Project description:Identifying actionable targets through integrative analyses of GEM model and human prostate cancer profiling

| PRJNA260914 | ENA

Gene expression of VPA and GEM

Project description:Background: Histone deacetylase (HDAC) is strongly associated with epigenetic regulation and carcinogenesis, and its inhibitors induce the differentiation or apoptosis of cancer cells. Valproic acid (VPA) is one of the clinically available HDAC inhibitors. We investigated the anticancer effects of VPA in combination with gemcitabine (GEM) in cholangiocarcinoma cell line, and explored the mechanisms of the anticancer effects using microarray analysis. Methods: A human cholangiocarcinoma cell line (HuCCT1) was used. The anticancer effects of VPA, or gemcitabine (GEM), and the effects of VPA combined with GEM, were studied by cell proliferation assay. The microarray analysis was performed, the genes were picked up using Gene Spring GX11.5, Ingenuity Pathways Analysis (IPA) was performed, and then the gene-expression was determined by RT-PCR. Results: GEM (5nM) and VPA (0.5mM) reduced by 23%, which significantly augmented the anticancer effect of GEM alone or VPA alone (P<0.01). Using the microarray analysis, forty-three genes were identified with the comparison between GEM group and GEM plus VPA combination group. The interactions were shown between genes of the “Cellular Development” relevant to the differentiation of cancer cell using IPA.

2011-02-09 | GSE27036 | GEO

Gene expression data from 4T1 cells stably transduced with lentiviral vectors encoding a control shRNA (shscramble) or two shRNAs targeting TM4SF1 (shTM4SF1-1 and shTM4SF1-5) and from 4TO7 cells stably expressing with or without TM4SF1

Project description:Compare the gene expression profile between shscramble with shTM4SF1 knockingdown 4T1 cells and between 4TO7 cells stably expressing with or without TM4SF1 Compare the gene expression profile between shscramble with shTM4SF1 knockingdown 4T1 cells and between 4TO7 cells stably expressing with or without TM4SF1

2016-06-11 | E-GEOD-62730 | biostudies-arrayexpress

Dexamethasone treatment of VCaP prostate cells

Project description:The treatment of advanced prostate cancer has been transformed by novel antiandrogen therapies such as enzalutamide. We identified glucocorticoid receptor (GR) activity as modulator of enzalutamite sensitivity in the VCaP prostate cancer cell line. The GR agonist dexamethasone was sufficient to confer enzalutamide resistance whereas a GR antagonist restored sensitivity. These expression profiling data demonstrate that GR transcriptional activity overlaps with that of AR in the VCAP model. VCAP cells growing in complete media were treated with the indicated drugs in biological triplicates for 24 hours prior to harvest.

2013-12-27 | E-GEOD-51872 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data